CA2336602C - Companion animal therapeutic treat - Google Patents
Companion animal therapeutic treat Download PDFInfo
- Publication number
- CA2336602C CA2336602C CA2336602A CA2336602A CA2336602C CA 2336602 C CA2336602 C CA 2336602C CA 2336602 A CA2336602 A CA 2336602A CA 2336602 A CA2336602 A CA 2336602A CA 2336602 C CA2336602 C CA 2336602C
- Authority
- CA
- Canada
- Prior art keywords
- sea cucumber
- jerky
- weight
- dosage form
- palatable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 title claims description 12
- 241000251511 Holothuroidea Species 0.000 claims abstract description 34
- 235000019629 palatability Nutrition 0.000 claims abstract description 15
- 230000002917 arthritic effect Effects 0.000 claims abstract description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 4
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract description 4
- 235000016709 nutrition Nutrition 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract 9
- 235000013372 meat Nutrition 0.000 claims description 15
- 235000020688 green tea extract Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 239000006227 byproduct Substances 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 6
- 229960002442 glucosamine Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 229940094952 green tea extract Drugs 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 11
- 244000269722 Thea sinensis Species 0.000 abstract description 9
- 235000009569 green tea Nutrition 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 241000282326 Felis catus Species 0.000 abstract description 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000013311 vegetables Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 6
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 6
- 241000512259 Ascophyllum nodosum Species 0.000 description 6
- 150000002302 glucosamines Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000005081 epithelial layer Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000008355 cartilage degradation Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001505481 Cucumaria frondosa Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003846 cartilage breakdown Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003042 chondroprotective agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a palatable dosage form of a "jerky stick" or treat for companion animals which includes sea cucumber fractions alone or in combination with glucosamine sulfate and/or glucosamine hydrochloride, and/or sea vegetables, and/or green tea; such jerky stick containing an effective amount of sea cuccumber material for the inhibition or modulation or arthritic or nutritional problems in dogs or cats, and containing palatability co-factors which render the jerky stick attractive to the animal in need.
Description
COMPANION ANIMAL THERAPEUTIC TREAT
Field of the Invention The present invention involves the use of sea cucumber tissue fractions, in combination with kelp, and/or green tea extracts, for the inhibition of inflammation. These therapeutic fractions are incorporated with ingredients which provide palatability into a delivery system as a user-convenient and pet acceptable "jerky stick" or similar animal "treat" format.
Background of the Invention Dogs and other companion animals suffering from various forms of arthritis are in need of supplements which deliver active forms of anti-inflammatory agents in a palatable manner.
Glucosamine sulfate and glucosamine HCL and related products are described in various patents such as those by Henderson, et al, which teach the incorporation of glucosamines with other sulfated polysaccharides, vitamin C and manganese in products aimed at cartilage health. It is believed that glucosamine, or similar products, provide one or more of the biochemical components which make up the matrix of mammalian cartilage. Glucosamine is a chondroprotective agent which acts as a competitive inhibitor of inflammatory agents produced by the body which attack the cartilage and/or joint fluid in the joints.
Green tea extracts have been shown to be potent inhibitors of inflammation and collagen-induced arthritis in mice. See, Haqqi, et al., Proc. Natl.
Acad. Sci., USA, 96:4524-29 (1999). The polyphenolic subfraction of green tea, known as epigallocatechin-3-gallate (EGCg), has proven to be an inhibitor of cartilage degradation in mammals. Id. In an experiment, purified EGCg, from Sigma Chemical Supply, St. Louis, MO, was placed with bovine nasal cartilage explants at a concentration of 22iM. This mixture was cultured for 5 days in the presence or absence of the pro-inflammatory cytokine, recombinant human tumor necrosis factor alpha at 3nM. The inhibition of both the basal and stimulated protcoglycan degradation by EGCg was measured using a colorimetric assay for sulfated glycosaminoglycans. See, Farndale, et al., Biochem. Biophys. Acta, 4:883 (1986). The results showed that EGCg was a potent inhibitor of cartilage breakdown at the sub-cellular level.
Jerky sticks, as are known in the dog treat industry, are often combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols that are mixed and extruded into various shapes, weights, and sizes which can vary widely. See, U.S. patent No. 5,773,076 for a general description of the art. Jerky sticks are given to pets as rewards or for added nutrition, or both.
Field of the Invention The present invention involves the use of sea cucumber tissue fractions, in combination with kelp, and/or green tea extracts, for the inhibition of inflammation. These therapeutic fractions are incorporated with ingredients which provide palatability into a delivery system as a user-convenient and pet acceptable "jerky stick" or similar animal "treat" format.
Background of the Invention Dogs and other companion animals suffering from various forms of arthritis are in need of supplements which deliver active forms of anti-inflammatory agents in a palatable manner.
Glucosamine sulfate and glucosamine HCL and related products are described in various patents such as those by Henderson, et al, which teach the incorporation of glucosamines with other sulfated polysaccharides, vitamin C and manganese in products aimed at cartilage health. It is believed that glucosamine, or similar products, provide one or more of the biochemical components which make up the matrix of mammalian cartilage. Glucosamine is a chondroprotective agent which acts as a competitive inhibitor of inflammatory agents produced by the body which attack the cartilage and/or joint fluid in the joints.
Green tea extracts have been shown to be potent inhibitors of inflammation and collagen-induced arthritis in mice. See, Haqqi, et al., Proc. Natl.
Acad. Sci., USA, 96:4524-29 (1999). The polyphenolic subfraction of green tea, known as epigallocatechin-3-gallate (EGCg), has proven to be an inhibitor of cartilage degradation in mammals. Id. In an experiment, purified EGCg, from Sigma Chemical Supply, St. Louis, MO, was placed with bovine nasal cartilage explants at a concentration of 22iM. This mixture was cultured for 5 days in the presence or absence of the pro-inflammatory cytokine, recombinant human tumor necrosis factor alpha at 3nM. The inhibition of both the basal and stimulated protcoglycan degradation by EGCg was measured using a colorimetric assay for sulfated glycosaminoglycans. See, Farndale, et al., Biochem. Biophys. Acta, 4:883 (1986). The results showed that EGCg was a potent inhibitor of cartilage breakdown at the sub-cellular level.
Jerky sticks, as are known in the dog treat industry, are often combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols that are mixed and extruded into various shapes, weights, and sizes which can vary widely. See, U.S. patent No. 5,773,076 for a general description of the art. Jerky sticks are given to pets as rewards or for added nutrition, or both.
Both extracts from the sea cucumber and from green tea are known to have beneficial therapeutic effects in mammals. These beneficial effects could not be utilized by veterinarians and others skilled in the art of animal care because they were not available in a palatable form. It is known to those skilled in the art of veterinary science that dogs and other mammals prefer palatability factors such as, fish, meat or meat by-products to enhance the attractiveness of therapeutic products and increase patient compliance.
Given the lack of a mode of delivery for these types of anti-inflammatory extracts that is both easy to administer for the caretaker and agreeable to the animal, there is a recognized need for the combination of an acceptable delivery form and the therapeutic extracts.
Summary of the Invention The present invention relates to a mode of delivery for biologically active fractions of sea cucumber and green tea. In this regard, the present invention describes a "jerky stick" or "dog bone" as is known in the art, being combined with the palatability factors of meat and meat by-products, garlic, smoke flavor or cheese, and the additional co-factors of glucosamine sulfate, glucosamine hydrochloride and/or green tea extracts or derivatives thereof for therapeutic treatment of inflammation and arthritis.
Detailed Description of the Invention The present invention addresses the problem of administration of anti-inflammatory treatments, specifically; sea cucumber products, glucosamines, kelps and green tea extracts by incorporating them into jerky treats with co-factors addressing the need to make the total product palatable to the animal in need.
The sea cucumber fraction delivery system for animals of the present invention includes the combination of glucosamines and/or kelp, and/or green tea extracts in the form, of a jerky stick, or "treat", as is popular in the dog-treat industry.
The "jerky stick" of the present invention combines certain ingredients and is made palatable by certain co-factors such as meats or flavorings known to those skilled in the art and include glucosamines or glucosamine derivatives. Sea cucumber body wall finely divided, including the epithelial layer, muscle layer and collagen layer as an ingredient in a formed dog jerky stick is also an aspect of the present invention.
These total sea cucumber skin fractions are also incorporated with glucosamines described above and formed in various percentages of incorporation into jerky sticks with palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds. A suitable range of glucosamine concentration is between 1% and 50% of the final product (by weight). These jerky sticks or manufactured "treats" are administered to dogs, cats and other animals and provide increased attractiveness to those animals in need of the therapeutic ingredients.
As used herein, the term "B1000" refers to the isolated epithelial layer of the sea cucumber, substantially free of the flower portion, muscle, collagenous tissues and viscera;
the term "T2000" refers to the isolated flower portion of the sea cucumber, substantially free of 5 other portions of the sea cucumber body;
the term "derivative" refers to any compound, fraction or combination thereof, derived from a sea cucumber or green tea fraction that has biological activity or nutritional properties;
the term "inflammation disorder" refers to any condition or disease in a warm-blooded animal having inflammation as a symptom or proximate cause.
In one embodiment of the invention the delivery form "jerky treat" material contains the sea cucumber fractions as disclosed in U.S. patent No. 5,770,205.
Active anti-inflammatory compositions can be obtained from sea cucumber in a variety of ways. For example, sea cucumbers can first be cleaned of muscle bands and viscera, boiled (but not salted), preferably for about 1-z hour, and then dried, preferably in low-heat mechanical driers such as those employing "heat pump"
technology. The dried tissue can further be ground or divided as needed for ultimate use. This process decreases the sodium content of the tissue and helps protect various active ingredients from degradation.
This fraction can be formulated and used directly as an anti-inflammatory composition.
Another active fraction can be obtained from the flower portion of the sea cucumber. During the evisceration process described above, the anterior portion ("flower") of the sea cucumber is cut away from the viscera and body wall. The isolated flower is then heated, preferably for about hour, dried at low temperatures (e.g. between about 140 F and about 180 F
using conventional drying apparatus and per known techniques). This dried fraction, designated "T2000"
by the inventor, can then be ground or divided as needed for formulation and use directly as an anti-inflammatory composition.
Still another anti-inflammatory fraction can be obtained from the epithelial layer of the sea cucumber body wall. Muscle, viscera and flower are removed as described above, followed by isolation of the epithelial layer of the sea cucumber body wall from the harder collagenous layers beneath, preferably by one or more of the following means:
- heating the body-wall in water at temperatures from about 140 F to about 180 F, preferably at about 170 F, followed by mechanical separation by hand or machine (e.g., .using machines known in the art as mincers or de-boners, which detect tissue density and separate harder tissues from softer tissues);
- enzymatic hydrolytic separation, using, e.g., organism's own digestive tract enzymes, proteases from mammalian sources, proteases from non-mammalian sources or acidic hydrolazes, preferably Alcalase1"(NOVO Nordisk Bio Chem, North Carolina), the enzyme preferably being in a solution of about 1% to about 10% enzyme, most preferably in a solution of about 10% enzyme;
- scouring/scrubbing or de-boning processes known to those skilled in the potato or chicken processing arts.
Given the lack of a mode of delivery for these types of anti-inflammatory extracts that is both easy to administer for the caretaker and agreeable to the animal, there is a recognized need for the combination of an acceptable delivery form and the therapeutic extracts.
Summary of the Invention The present invention relates to a mode of delivery for biologically active fractions of sea cucumber and green tea. In this regard, the present invention describes a "jerky stick" or "dog bone" as is known in the art, being combined with the palatability factors of meat and meat by-products, garlic, smoke flavor or cheese, and the additional co-factors of glucosamine sulfate, glucosamine hydrochloride and/or green tea extracts or derivatives thereof for therapeutic treatment of inflammation and arthritis.
Detailed Description of the Invention The present invention addresses the problem of administration of anti-inflammatory treatments, specifically; sea cucumber products, glucosamines, kelps and green tea extracts by incorporating them into jerky treats with co-factors addressing the need to make the total product palatable to the animal in need.
The sea cucumber fraction delivery system for animals of the present invention includes the combination of glucosamines and/or kelp, and/or green tea extracts in the form, of a jerky stick, or "treat", as is popular in the dog-treat industry.
The "jerky stick" of the present invention combines certain ingredients and is made palatable by certain co-factors such as meats or flavorings known to those skilled in the art and include glucosamines or glucosamine derivatives. Sea cucumber body wall finely divided, including the epithelial layer, muscle layer and collagen layer as an ingredient in a formed dog jerky stick is also an aspect of the present invention.
These total sea cucumber skin fractions are also incorporated with glucosamines described above and formed in various percentages of incorporation into jerky sticks with palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds. A suitable range of glucosamine concentration is between 1% and 50% of the final product (by weight). These jerky sticks or manufactured "treats" are administered to dogs, cats and other animals and provide increased attractiveness to those animals in need of the therapeutic ingredients.
As used herein, the term "B1000" refers to the isolated epithelial layer of the sea cucumber, substantially free of the flower portion, muscle, collagenous tissues and viscera;
the term "T2000" refers to the isolated flower portion of the sea cucumber, substantially free of 5 other portions of the sea cucumber body;
the term "derivative" refers to any compound, fraction or combination thereof, derived from a sea cucumber or green tea fraction that has biological activity or nutritional properties;
the term "inflammation disorder" refers to any condition or disease in a warm-blooded animal having inflammation as a symptom or proximate cause.
In one embodiment of the invention the delivery form "jerky treat" material contains the sea cucumber fractions as disclosed in U.S. patent No. 5,770,205.
Active anti-inflammatory compositions can be obtained from sea cucumber in a variety of ways. For example, sea cucumbers can first be cleaned of muscle bands and viscera, boiled (but not salted), preferably for about 1-z hour, and then dried, preferably in low-heat mechanical driers such as those employing "heat pump"
technology. The dried tissue can further be ground or divided as needed for ultimate use. This process decreases the sodium content of the tissue and helps protect various active ingredients from degradation.
This fraction can be formulated and used directly as an anti-inflammatory composition.
Another active fraction can be obtained from the flower portion of the sea cucumber. During the evisceration process described above, the anterior portion ("flower") of the sea cucumber is cut away from the viscera and body wall. The isolated flower is then heated, preferably for about hour, dried at low temperatures (e.g. between about 140 F and about 180 F
using conventional drying apparatus and per known techniques). This dried fraction, designated "T2000"
by the inventor, can then be ground or divided as needed for formulation and use directly as an anti-inflammatory composition.
Still another anti-inflammatory fraction can be obtained from the epithelial layer of the sea cucumber body wall. Muscle, viscera and flower are removed as described above, followed by isolation of the epithelial layer of the sea cucumber body wall from the harder collagenous layers beneath, preferably by one or more of the following means:
- heating the body-wall in water at temperatures from about 140 F to about 180 F, preferably at about 170 F, followed by mechanical separation by hand or machine (e.g., .using machines known in the art as mincers or de-boners, which detect tissue density and separate harder tissues from softer tissues);
- enzymatic hydrolytic separation, using, e.g., organism's own digestive tract enzymes, proteases from mammalian sources, proteases from non-mammalian sources or acidic hydrolazes, preferably Alcalase1"(NOVO Nordisk Bio Chem, North Carolina), the enzyme preferably being in a solution of about 1% to about 10% enzyme, most preferably in a solution of about 10% enzyme;
- scouring/scrubbing or de-boning processes known to those skilled in the potato or chicken processing arts.
Heating in water, followed by mechanical separation using a de-boner is most preferred.
The epithelial fraction so obtained (designated "B1000" by the inventor) is a dark, moist, viscous, carbohydrate-rich matter. B1000 can be dried as described above, formulated and used directly as an anti-inflammatory composition.
Once produced, the B1000 and/or T2000 fractions, other sea cucumber tissues, and kelp, are incorporated into the mixture for the preparation of the "jerky treats" in amounts between 1% and 80% by weight. These therapeutic constituents are then added to the combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols and palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds that are mixed and extruded into various shapes, weights, and sizes which can vary widely.
In another embodiment of the invention, green tea or green tea extracts are added to the formulation.
Green tea is known to contain potent inhibitors of cartilage degradation, for example EGCg, and is a useful adjunct for treating individuals with inflammatory diseases, such as arthritis, that can lead to cartilage degradation. Green tea can be water and alcohol extracted by methods known in the art whereby the phenolic fraction is between 30% and 70%. Green tea extracts having 30%, 50%, 60% and 100% enriched polyphenolics, or specifically green tea catechins, are available commercially and are suitable for use in the present invention. Extracts are incorporated into the "jerky stick" of the present invention at percentages of weight between 1% and 80% of the total "jerky stick"
delivery form. Alternatively, the pure compound EGCg can be added directly to the "jerky stick" formulation in amounts ranging up to 60% by weight or more, limited by factors such as LD50 and the physical considerations of maintaining a palatable consistency to the product.
Example 1 Preparation of the "Jerky Stick"
With Sea Cucumber and Kelp Fractions Jerky sticks were prepared using T2000 from the Sea Cucumber, Cucumaria frondosa, as described above.
T2000, together with various palatability factors including, but not limited to, meat, meat by-products and "Norwegian" kelp, Ascophylum nodosum, were added to vitamin E, garlic, lecithin, gelatin, glucosamine (as a hydrochloride salt, although the sulfate salt or any other suitable form) and flax seeds. The T2000 was added at about 8% of the final treat product by weight.
The glucosamine constituent was added at 2% of the final treat product by weight. The ingredient mix was then extruded and molded into a jerky stick shape 5 inches long, 1.25 inches wide and approximately 0.25 inches thick, with final weight of 14 grams.
The epithelial fraction so obtained (designated "B1000" by the inventor) is a dark, moist, viscous, carbohydrate-rich matter. B1000 can be dried as described above, formulated and used directly as an anti-inflammatory composition.
Once produced, the B1000 and/or T2000 fractions, other sea cucumber tissues, and kelp, are incorporated into the mixture for the preparation of the "jerky treats" in amounts between 1% and 80% by weight. These therapeutic constituents are then added to the combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols and palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds that are mixed and extruded into various shapes, weights, and sizes which can vary widely.
In another embodiment of the invention, green tea or green tea extracts are added to the formulation.
Green tea is known to contain potent inhibitors of cartilage degradation, for example EGCg, and is a useful adjunct for treating individuals with inflammatory diseases, such as arthritis, that can lead to cartilage degradation. Green tea can be water and alcohol extracted by methods known in the art whereby the phenolic fraction is between 30% and 70%. Green tea extracts having 30%, 50%, 60% and 100% enriched polyphenolics, or specifically green tea catechins, are available commercially and are suitable for use in the present invention. Extracts are incorporated into the "jerky stick" of the present invention at percentages of weight between 1% and 80% of the total "jerky stick"
delivery form. Alternatively, the pure compound EGCg can be added directly to the "jerky stick" formulation in amounts ranging up to 60% by weight or more, limited by factors such as LD50 and the physical considerations of maintaining a palatable consistency to the product.
Example 1 Preparation of the "Jerky Stick"
With Sea Cucumber and Kelp Fractions Jerky sticks were prepared using T2000 from the Sea Cucumber, Cucumaria frondosa, as described above.
T2000, together with various palatability factors including, but not limited to, meat, meat by-products and "Norwegian" kelp, Ascophylum nodosum, were added to vitamin E, garlic, lecithin, gelatin, glucosamine (as a hydrochloride salt, although the sulfate salt or any other suitable form) and flax seeds. The T2000 was added at about 8% of the final treat product by weight.
The glucosamine constituent was added at 2% of the final treat product by weight. The ingredient mix was then extruded and molded into a jerky stick shape 5 inches long, 1.25 inches wide and approximately 0.25 inches thick, with final weight of 14 grams.
Example 2 Preparation of the "Jerky Stick"
With Additional Green Tea Fractions The jerky stick was produced as in Example 1, with the addition of a green tea extract containing 30%
polyphenolics. The green tea extract, purchased from Indena USA. Seattle WA, USA, Product 36TVD0090-"THE
VERT" AQ-ATO-HF, was added to the above recipe at 2% by weight, but can be added at any percentage of the jerky stick weight between 1% and 30% (limited by palatability). This provided an effective dose of 280 milligrams of the green tea extract to the jerky product. It is contemplated that the epigallocatechin-3-gallate (EGCg) is absorbed systemically in mammals, and is effective in inhibiting degradation of cartilage in arthritic joints. In addition, EGCg is thought to provide added synergy to the anti-inflammatory activity of the sea cucumber and the sea cucumber plus glucosamine compounds.
Example 3 Effectiveness and Palatability of the "Jerky Stick"
in Arthritic Dogs Jerky sticks with added green tea extracts were administered to 4 dogs of unknown breeds at Westside Animal Clinic in Richmond, IN and were found to be palatable.
Further, six arthritic dogs in various conditions of lameness were administered jerky sticks as prepared in Example 1. After two weeks of administration at one stick per day per 50 pounds of weight, these dogs showed increased mobility as determined by both their owners and veterinarians. In every instance, palatability was not a problem in administration of the 5 jerky.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons of 10 ordinary skill in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
With Additional Green Tea Fractions The jerky stick was produced as in Example 1, with the addition of a green tea extract containing 30%
polyphenolics. The green tea extract, purchased from Indena USA. Seattle WA, USA, Product 36TVD0090-"THE
VERT" AQ-ATO-HF, was added to the above recipe at 2% by weight, but can be added at any percentage of the jerky stick weight between 1% and 30% (limited by palatability). This provided an effective dose of 280 milligrams of the green tea extract to the jerky product. It is contemplated that the epigallocatechin-3-gallate (EGCg) is absorbed systemically in mammals, and is effective in inhibiting degradation of cartilage in arthritic joints. In addition, EGCg is thought to provide added synergy to the anti-inflammatory activity of the sea cucumber and the sea cucumber plus glucosamine compounds.
Example 3 Effectiveness and Palatability of the "Jerky Stick"
in Arthritic Dogs Jerky sticks with added green tea extracts were administered to 4 dogs of unknown breeds at Westside Animal Clinic in Richmond, IN and were found to be palatable.
Further, six arthritic dogs in various conditions of lameness were administered jerky sticks as prepared in Example 1. After two weeks of administration at one stick per day per 50 pounds of weight, these dogs showed increased mobility as determined by both their owners and veterinarians. In every instance, palatability was not a problem in administration of the 5 jerky.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons of 10 ordinary skill in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
Claims (7)
1. A palatable dosage form for administering a therapeutic agent to an animal in need thereof comprising between 1% and 80% by weight of fractions of sea cucumber between 1% and 50% by weight glucosamine HCL or glucosamine sulfate and one or more palatability factors in an amount sufficient to render the dosage form palatable to a target animal, wherein said dosage form is of a weight between 1 gram and 30 grams.
2. Use of a palatable jerky treat dosage form to deliver sea cucumber fractions to an animal in need thereof, wherein said palatable jerky treat dosage form comprises between 1%
and 80% by weight sea cucumber fractions and one or more palatability factors.
and 80% by weight sea cucumber fractions and one or more palatability factors.
3. Use of a palatable jerky treat dosage form comprising sea cucumber fractions to provide increased mobility and relieve nutritional and arthritic or inflammatory symptoms in an animal in need thereof, wherein said palatable jerky treat dosage form comprises between 1% and 90% by weight glucosamine or a salt thereof, between 1% and 90% by weight sea cucumber fractions and one or more palatability factors.
4. The palatable dosage form of claim 1, additionally comprising green tea extract in an effective amount to inhibit inflammation in a mammal in need thereof.
5. A therapeutic jerky treat for treatment of inflammation in a dog comprising between 1% and 80% by weight of fractions of sea cucumber tissues, and one or more palatability factors selected from the group consisting of beef, meat meal, meat by-products, and fish by-products.
6. The therapeutic jerky treat of claim 5 further comprising green tea extract.
7. A method for preparing a therapeutic jerky treat having an active fraction of sea cucumber which comprises mixing from 1% to 80% by weight of an active sea cucumber fraction with at least one palatability factor and extruding said mixture to form a jerky stick, wherein said active sea cucumber fraction is prepared by boiling and then drying cleaned sea cucumber.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9441898P | 1998-07-07 | 1998-07-07 | |
US60/094,418 | 1998-07-07 | ||
US13769999P | 1999-06-07 | 1999-06-07 | |
US60/137,699 | 1999-06-07 | ||
PCT/US1999/015168 WO2000001399A1 (en) | 1998-07-07 | 1999-07-06 | Companion animal therapeutic treat |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2336602A1 CA2336602A1 (en) | 2000-01-13 |
CA2336602C true CA2336602C (en) | 2010-11-02 |
Family
ID=26788849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2336602A Expired - Fee Related CA2336602C (en) | 1998-07-07 | 1999-07-06 | Companion animal therapeutic treat |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2002519384A (en) |
AU (1) | AU770392B2 (en) |
CA (1) | CA2336602C (en) |
GB (1) | GB2355196B (en) |
WO (1) | WO2000001399A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
MXPA02010766A (en) * | 2000-05-01 | 2003-10-06 | Iams Company | Process for enhancing immune response in canines using a dietary composition including garlic. |
US6689391B2 (en) | 2001-03-30 | 2004-02-10 | Council Of Scientific & Industrial Research | Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses |
US6916492B2 (en) | 2001-03-30 | 2005-07-12 | Council Of Scientific & Industrial Research | Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses |
US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
JP4757413B2 (en) * | 2001-09-11 | 2011-08-24 | 株式会社高研 | Sponge made of sea cucumber or starfish collagen and method for producing the same |
FR2831396B1 (en) * | 2001-10-31 | 2004-04-02 | Moulin Du Chatel | FOOD FOR LAYING HENS FOR THE PRODUCTION OF IODIZED AND POLYUNSATURATED FATTY EDIBLE EGGS AND PROCESS FOR SUPPLYING CORRESPONDING LAYING HENS |
CN1771046A (en) * | 2003-04-11 | 2006-05-10 | 协和发酵工业株式会社 | Preventive or remedy for arthritis |
CN102934819B (en) * | 2012-10-26 | 2014-04-02 | 青岛佳日隆海洋食品有限公司 | Trepang capsule and preparation process thereof |
GB201414910D0 (en) * | 2014-05-23 | 2014-10-08 | Mars Inc | Composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1044707B (en) * | 1968-10-26 | 1980-04-21 | Rotta Research Lab | PROCEDURE FOR THE PREPARATION OF GLUCOSANINE SALTS AND PHARMACEUTICAL PREPARATIONS INCLUDING THESE GLUCOSAMINE SALTS AS ACTIVE AGENTS |
US4975270A (en) * | 1987-04-21 | 1990-12-04 | Nabisco Brands, Inc. | Elastomer encased active ingredients |
JPH0491027A (en) * | 1990-08-02 | 1992-03-24 | Taiho Yakuhin Kogyo Kk | Therapeutic agent of human immune deficiency virus |
JPH04117329A (en) * | 1990-09-05 | 1992-04-17 | Shiseido Co Ltd | Composition showing activity related to dissolution of thrombosis |
CN1050680A (en) * | 1990-10-05 | 1991-04-17 | 刘辉明 | The manufacture method of Haicibao liquid |
CN1045538C (en) * | 1993-08-04 | 1999-10-13 | 成都市疑难病研究所 | Natural composition oral medicine for treating male sterility |
US5474033A (en) * | 1994-05-05 | 1995-12-12 | Mitchell, Jr.; Robert K. | Animal teaching/amusement device |
US5464619A (en) * | 1994-06-03 | 1995-11-07 | The Procter & Gamble Company | Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability |
FR2745978B1 (en) * | 1996-03-18 | 1998-07-17 | ORAL TREATMENT PRODUCT FOR ANIMALS | |
US5770205A (en) * | 1996-08-05 | 1998-06-23 | Coastside Bio Resources | Tissue fractions of sea cucumber for the treatment of inflammation |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
-
1999
- 1999-07-06 AU AU49694/99A patent/AU770392B2/en not_active Ceased
- 1999-07-06 GB GB0100640A patent/GB2355196B/en not_active Expired - Fee Related
- 1999-07-06 WO PCT/US1999/015168 patent/WO2000001399A1/en active IP Right Grant
- 1999-07-06 CA CA2336602A patent/CA2336602C/en not_active Expired - Fee Related
- 1999-07-06 JP JP2000557845A patent/JP2002519384A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2336602A1 (en) | 2000-01-13 |
GB2355196A (en) | 2001-04-18 |
GB0100640D0 (en) | 2001-02-21 |
AU770392C (en) | 2000-01-24 |
AU4969499A (en) | 2000-01-24 |
AU770392B2 (en) | 2004-02-19 |
JP2002519384A (en) | 2002-07-02 |
GB2355196B (en) | 2004-06-09 |
WO2000001399A1 (en) | 2000-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900002027B1 (en) | Dietary products and uses comprising methylsulfonylmethane | |
RU2230458C2 (en) | Fodder for domestic animals, method for its preparing and therapeutic method for maintaining healthy joints and deterioration of arthritic symptoms in domestic animals | |
US20120004157A1 (en) | Hydroxyproline compositions and uses thereof | |
US11191814B2 (en) | Pet food formulation with cannabinoids | |
JP6149906B2 (en) | Product for feeding an animal and process for producing the product for feeding an animal | |
US6428817B1 (en) | Companion animal therapeutic treat | |
US20080069862A1 (en) | Joint preserving nutritional vitamin, mineral and herbal pet supplement | |
CN1668212A (en) | Compositions comprising lactoferrin | |
CA2336602C (en) | Companion animal therapeutic treat | |
KR100973192B1 (en) | A composition of the functional feed for aged pets | |
BG107626A (en) | Application of benzophenanthridine alcaloids as fodder additive and medicamentous form against intestinal inflammation | |
KR100215995B1 (en) | Food additive composition for promoting the growth of fish | |
WO1990009179A1 (en) | Treatment of tibial dyschondroplasia | |
El-Shafei et al. | Effectiveness of caprylic acid and Yucca schidigera extract on productive and physiological performance of laying hens | |
JPWO2006120974A1 (en) | Health food and pharmaceutical composition for improving diseases of cartilage metabolism disorder | |
US20100316732A1 (en) | Beverage compositions for the promotion of joint health in companion animals | |
KR20040102963A (en) | Feed composition for domestic animals containing fructus chebulae | |
JP2001314173A (en) | Composition for food | |
EP1834647A1 (en) | Canine and equine collagen joint health supplement | |
Dharmayudha et al. | Soil worms (Lumbricus rubellus) as feed additives for piglets' growth, blood profile and immunomodulators | |
JP2001089384A (en) | Feed for treatment for animal | |
CN116998622A (en) | Weaning feed for pet dog cubs and preparation method thereof | |
JPH06327412A (en) | Growth-promoting or improving feed and method | |
JPH04120022A (en) | Bone health enhancing agent of bone and production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190708 |
|
MKLA | Lapsed |
Effective date: 20190708 |